




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C12N 15/62, A61K 39/00 C12N 5/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 92/20805 (43) International Publication Date: 26 November 1992 (26.11.92)</p>
<p>(21) International Application Number: PCT/SE92/00304 (22) International Filing Date: 11 May 1992 (11.05.92) (30) Priority data: 9101433-2 13 May 1991 (13.05.91) SE (71) Applicant (for all designated States except US): PIERRE FABRE MEDICAMENT [FR/FR]; 45, place Abel-Gance, F-92100 Boulogne (FR). (72) Inventors; and (75) Inventors/Applicants (for US only) : STÅHL, Stefan [SE/SE]; Armégatan 32/523, S-171 59 Solna (SE). NYGREN, Per-Åke [SE/SE]; Pilotgatan 22, S-122 51 Enskede (SE). HANSSON, Marianne [SE/SE]; Blåsutvägen 13, S-122 30 Enskede (SE). UHLÉN, Mathias [SE/SE]; Kvarnbogatan 30, S-752 39 Uppsala (SE). NGUYEN, Thien, Ngoc [FR/FR]; 2, rue Général-Pacthod, F-74160 S.-Julien-en-Genevois (FR).</p>		<p>(74) Agent: AWAPATENT AB; Box 45086, S-104 30 Stockholm (SE). (81) Designated States: AT (European patent), AU, BE (European patent), BF (OAPI patent), BJ (OAPI patent), CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), ML (OAPI patent), MR (OAPI patent), NL (European patent), SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US. Published With international search report.</p>

(54) Title: RECOMBINANT DNA CODING FOR SIGNAL PEPTIDE, SELECTIVE INTERACTING POLYPEPTIDE AND MEMBRANE ANCHORING SEQUENCE

Cell wall Cell membrane



(57) Abstract

Recombinant DNA sequence comprising a first DNA fragment coding for a first amino acid sequence operating as a signal peptide operable in a Gram positive host, operatively linked to a second DNA fragment coding for a second amino acid sequence not naturally found on the surface of Gram positive bacteria and capable of selective interaction, said second DNA fragment being operatively linked to a third DNA fragment coding for a third amino acid sequence operable in a Gram positive host as a cell wall spanning and membrane anchoring sequence; an expression vector or plasmid containing such recombinant DNA sequence; Gram positive bacterial cell containing such vector or plasmid; and a process for selective isolation or identification of Gram positive bacterial cells.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

RECOMBINANT DNA CODING FOR SIGNAL PEPTIDE; SELECTIVE
INTERACTING POLYPEPTIDE AND MEMBRANE ANCHORING SEQUENCE

The present invention relates to a recombinant DNA
5 sequence substantially comprising three different DNA
fragments, and to expression vectors or plasmids con-
taining such sequence, as well as Gram positive bacterial
cells harbouring such DNA sequence or being transformed by
a vector or plasmid as indicated. The invention further-
10 more involves a process for selective isolation or identi-
fication of Gram positive bacterial cells.

The present invention involves new useful techniques
based on an entirely new concept involving utilization of
surface receptor structures found on bacterial cells.
15 These new techniques find many interesting applications,
the two major aspects of the invention residing in cura-
tive or preventive immunology on the one hand and practi-
cal processes for selective isolation or identification of
Gram positive bacterial cells on the other hand.

20 In modern vaccinology there is a great interest in
the development of live delivery systems for recombinant
immunogens, as live organisms often show enhanced immuno-
genicity over killed or subunit vaccine preparations. A
number of live recombinant attenuated viruses have been
25 tried as carriers of foreign epitopes. These include
vaccinia virus (Moss et al., Nature 311, 67-69 (1984)),
adenovirus (Ballay et al., EMBO J. 4, 3861-3865 (1985)),
poliovirus (Evans et al., Nature 339, 385-388 (1989)) and
herpesvirus (Shih et al., Proc.Natl.Acad.Sci. USA 81,
30 5867-5870 (1984)). Also bacterial systems, using live re-
combinant bacteria, such as Salmonella (Hosieth and
Stocker, Nature 291, 238-239 (1981)), mycobacteria (Jacobs
et al., Nature 327, 532-535 (1987)) and E.coli
(O'Callaghan et al., Res.Microbiol. 141, 963-969 (1990)),
35 have been developed where the whole bacterium is used as a
carrier of the recombinant immunogen.

Furthermore, modern recombinant DNA techniques have made it possible to isolate and clone antibody genes directly from immunized animals or from in vitro immunized lymphocytes (Huse et al., Science, 1989, 246, 1275-1280) 5 (Borrebaeck et al., Proc.Natl.Acad.Sci. USA 1988, 85, 3995-3999). Genetic libraries of the antibody repertoire can be established in bacterial vector systems, allowing easy in vitro manipulation of the isolated immunoglobulin genes.

10 By "random" combination of genes encoding the variable regions derived from heavy (VH) and light (VL) chains, and the subsequent expression in a bacterial host, new formations of VH/VL pairs are obtained that can be screened for binding characteristics. (Huse et al., 15 Science, 1989, 246, 1275-1280). However, the large number of clones generated using this strategy calls for efficient screening methods to enable isolation of relevant clones in a practical manner. Recently, a strategy has been described employing bacterial phages as carriers of 20 surface exposed immunoglobulin fragments, allowing selection of single phage particles bearing combinations of VH/VL domains capable of binding a desired antigen (McCafferty et al., 1990, Nature, 348, 552-554).

The importance of new techniques for the clone specific 25 isolation of vehicles carrying unique surface exposed structures also relate to fields such as hormone-hormone receptor recognition (Bass et al., Proteins: Structure, Function and Genetics, 8, 309-314 (1990)) and enzyme-substrate compatibility (Carter et al., Proteins: Structure, 30 Function and Genetics, 6, 240-248 (1989)).

However, structural constraints for the incorporation of immunoglobulin segments into the phage coat protein employed can result in negative biological selection and subsequent loss of the theoretical repertoire of VH/VL 35 combinations. Moreover, the small number of immunoglobulin molecules exposed on each phage particle, from 1 to about 5 molecules, can result in insurmountable problems with

regard to the recovery of combinations with moderate binding capabilities due to the low overall affinity of the phage particle.

Also systems for displaying heterologous proteins on the surface of Escherichia coli have been described, such as fusions of antigenic peptides to the flagellor filament (Ku wajima et al., 1988, Bio/Technology, 6, 1080-1083) or the outer membrane protein Lam B (O'Callaghan et al., 1990, Res.Microbiol. 141, 963-969). Here, again, there are structural constraints that make such concept less useful in practical applications.

The present invention has for its main object to provide new techniques based on the concept of using recombinant surface receptor structures for a wide spectrum of practical applications.

Another object of the invention is to use Gram positive bacteria as carriers for the presentation of immunogenes, whereby the immunogenic response is greatly improved and the use of conventional adjuvants less critical or even superfluous.

Yet another object of the invention is to provide techniques enabling identification and/or isolation of Gram positive bacterial cells from a heterologous population of such cells carrying different recombinant surface receptor structures.

Further objects of the invention are to provide recombinant DNA sequences, expression vectors or plasmids containing such sequences and Gram positive bacterial cells harbouring such sequences or being transformed by such vector or plasmid.

For these and other purposes that will be evident from the following description the present invention provides a recombinant DNA sequence comprising a first DNA fragment coding for a first amino acid sequence operating as a signal peptide operable in a Gram positive host, operatively linked to a second DNA fragment coding for a second amino acid sequence not naturally found on the sur-

face of Gram positive bacteria and capable of selective interaction, said second DNA fragment being operatively linked to a third DNA fragment coding for a third amino acid sequence operable in a Gram positive host as a cell wall spanning and membrane anchoring sequence.

In such recombinant DNA sequence said second amino acid sequence may be capable of antigenic action or may be constituted by an antibody (immunoglobulin) or an active fragment thereof.

In accordance with a preferred embodiment of the invention the recombinant DNA sequence is such wherein said third DNA fragment codes for the cell wall spanning and membrane anchoring region of staphylococcal protein A or streptococcal protein G.

In accordance with a preferred aspect of the invention said first DNA fragment originates from a Gram positive bacterial cell, such as a DNA fragment coding for the signal peptide of staphylococcal protein A.

Said third DNA fragment preferably codes for the cell wall spanning and membrane anchoring region of staphylococcal protein A.

With regard to the immunological aspect of the invention it is preferred that said second DNA fragment codes for an amino acid sequence capable of eliciting an immunogenic response that will be useful for vaccination purposes or for the production of antibodies.

The invention also involves the provision of an expression vector or plasmid containing a recombinant DNA sequence as outlined above. Such vector or plasmid is in accordance with the invention capable of replicating in a Gram positive bacterial host.

Furthermore, the invention covers Gram positive bacterial cells harbouring a recombinant DNA sequence as defined above or transformed by a vector or plasmid containing such recombinant DNA sequence.

Finally, the invention provides a process for selective isolation or identification of Gram positive bacterial cells from a heterologous population of such cells, wherein the cells carry different recombinant surface receptor structures, although each individual cell carries multiple copies of a specific recombinant surface receptor structure. Such process involves the step of allowing said heterologous population of cells to interact with a specific interacting partner, such as an antigen, enabling identification and/or isolation of cells carrying one specific recombinant surface receptor structure. According to one aspect of such inventive process said receptor structures may be constituted by antibodies or active fragments thereof.

It is preferred that said interacting partner is used in an immobilized form, whereby cells carrying a specific structure can be efficiently isolated. Such immobilization is preferably performed onto a solid support, such as in the form of a column.

The present invention will be further illustrated more in detail in the following description of specific embodiments presented in the form of examples. These examples refer to the appended figures 1 to 9, the contents of which will be clear from the legends to figures below.

Starting materials

Bacterial strains and cloning vectors

Escherichia coli strain RR1AM15 (Rüther, U., Nucl. Acids Res. 10, 5765-5772 (1982)) was used for the E.coli expression and the plasmid constructions. Staphylococcus xylosus KL117 (Schleifer and Kloos, Int. J. Syst. Bacteriol. 25, 50-61 (1975)) was used for the expression of recombinant proteins on the cell surface. pRIT28 (Hultman et al, Nucleos. and Nucleot. 7, 629-637 (1988)) pUC19 (Yanisch-Perron C., Vieira J. and Messing J., Gene 33, 103-119 (1985)) pRIT24 (Hammarberg et al, Proc. Natl. Acad. Sci. 86, 4367-4371 (1989)) pHERAT and pLERAT (A kind

gift from Dr. Greg Winter MRC, Cambridge, United Kingdom).

All strains, vectors, oligonucleotides and antibodies used in the examples are available at the Department of Biochemistry and Biotechnology at the Royal Institute of Technology, Stockholm, Sweden.

The vectors pSBB-M3-XM and pSBB-ScFv(D1.3)-XM have been deposited on May 10, 1991, at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH in Braunschweig, Germany and given the accession numbers DSM 6516 and DSM 6517 respectively, in accordance with the Budapest treaty.

Broth

Tryptic Soy Broth (30g/l) with Yeast Extract (5 g/l) was from Difco Inc. and dissolved in sterile water and autoclaved before the appropriate antibiotic was added.

15 Buffers

TST:Tris/HCl 25 mM pH7.4, 150 mM NaCl, 0.05% Tween
20. PBS:0.05 M sodium phosphate pH 7.1, 0.15 M NaCl.

PCR amplification

PCR amplifications were performed on a Techne Programmable Dri Block PHC-1



10 x PCR buffer: 100mM TRIS/HCl, pH 8.3, 500 mM KCl,
20mM Mg²⁺, 1% Tween 20, 2mM dNTP's and
oligo nucleotide primers as described
in the examples [5 pmole of each]

25 DNA polymerase: 0.5 units of Ampli Taq ® [Perkin Elmer Corp.]

PCR programme: 97°C, 0.5 minutes; 65°C, 1.0 minutes;
72°C, 1.0 minutes.

30

35

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page <u>6</u> , line <u>6-10</u> of the description ¹	
A. IDENTIFICATION OF DEPOSIT ²	
Further deposits are identified on an additional sheet <input type="checkbox"/> ³	
Name of depositary institution ⁴ DSM DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH	
Address of depositary institution (including postal code and country) ⁴ Mascheroder Weg 1-B D-3300 BRAUNSCHWEIG, Germany	
Date of deposit ⁵ 1992-05-10	Accession Number ⁶ DSM 6516 and DSM 6517
B. ADDITIONAL INDICATIONS ⁷ (leave blank if not applicable). This information is continued on a separate attached sheet <input type="checkbox"/>	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE ⁸ (if the indications are not for all designated States)	
D. SEPARATE FURNISHING OF INDICATIONS ⁹ (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later ⁹ (Specify the general nature of the indications e.g., "Accession Number of Deposit")	
E. <input checked="" type="checkbox"/> This sheet was received with the International application when filed (to be checked by the receiving Office)	
 _____ (Authorized Officer)	
<input checked="" type="checkbox"/> The date of receipt (from the applicant) by the International Bureau ¹⁰	
was	: 09 JUN 1992
 _____ (Authorized Officer)	

Oligonucleotides

KS1: 5'-CCGAATTCGCAGGTCCAACCTGAAGGAGTC-3'

KS2: 5'-CGAAGCTTTTAGGATCCTGAGGAGACTGTGAGAGTGG-3'

5 KS3: 5'-GCGAATTCGGACATCCAGATGACTCAGTC-3'

KS4: 5'-CGAAGCTTTTAGGATCCTTTGATTTCCAGCTTGGTGCC-3'

KS5: 5'-TGGACCCACCACCGCCCCGAGCCACC GCCACCTTTGATTTCCAG
CTTGGTGCC-3'10 KS6: 5'-GGGCGGTGGTGGGTCCATGGGCGGCGGATCTCAGGTCCAACCTG
AAGGAGTC-3'

STST 33: 5'-TTGGATCCTGCAGCAATTT-3'

STST 34: 5'-CCGAATTC AAGCTTCGCTCAAGCACCAAAAGAGGAAGAC
AATAAC-3'15 DNA sequencing

Solid phase DNA sequencing was performed in accordance to Hultman et al [Nucl. Acids. Res. 17, 4937-4946, (1989)].

Affinity purification of proteins [HSA and HEL]

20 Cells harbouring the different constructs were grown over night in broth supplemented with Ampicillin 100 mg/l. The medium was clarified by centrifugation at 5000 g first and then by a second centrifugation at 9000 g. Clarified medium was loaded directly on HSA-Sepharose or HEL-

25 Sepharose. After washing with 1xTST followed by 0.5 mM NH₄Ac, pH 5.0 proteins were eluted with 0.5 M HAc, pH 2.8. The absorbtion at 280 nm was measured and relevant fractions were lyophilized.

SDS PAGE

30 Proteins were dissolved and boiled for 5 min in 2.5% Sodium dodecyl sulphate [SDS], 5% dithiothreitol [DTT] and 0.01% Bromophenol Blue [BFB] before loaded onto a 10-15% gradient polyacrylamide gel for 30 min at 10 mA in accordance with the PHASTTM system [Pharmacia-LKB Biotechnology, 35 Sweden]. The gels were subsequently stained with Coomassie Brilliant Blue.

Routine methods

Methods used routinely in molecular biology are not described, such as restriction of DNA with endonucleases, ligation of DNA fragments etc.

5 Preparation and transformation of protoplasts

The preparations and transformations of protoplasts from S. xylosus were performed as described by Götz et al (J. Bacteriol. 145, 74-81 (1981)).

DNA preparations from staphylococci

10 Minipreparations of plasmid DNA from transformed staphylococci were performed using a modified alkaline extraction procedure (Birnboim and Doly, Nucl. Acids Res. 7, 1513-1523 (1979)). Cells harbouring the different constructs were grown over night in 1.5 ml broth supplemented
15 with Chloramphenicol 20 mg/l. Prior the standard protocol, the cells were incubated for one hour at 37°C with 5 µg lysostaphine in 100 µl saline buffer.

Rabbit antisera

20 The rabbit antiserum R120 was obtained from a rabbit immunized two times intramuscularly with 60 µg of preformed influenza membrane glycoprotein ISCOMs (Morein et al., Nature 308, 457-460 (1984)) covalently conjugated with a mixture of the fusion proteins ZZ-M3 and ZZ-M5 (Ståhl et al., Gene 89, 187-190 (1990)).

25 The preparation of the influenza ISCOMs and the coupling of the fusion proteins were performed as described by Lövgren et al. (J. Immunol. Meth. 98, 137-143 (1987)). The antiserum R120 reacted strongly with M3 peptide in ELISA and was non-reactive with the BB region and could consequently be used for the detection of M3 peptide on the
30 surface of staphylococci. The antiserum R102 was obtained from a rabbit immunized two times with the fusion protein BB-M5 (Ståhl et al., Gene 89, 187-190 (1990)) in Freund's Adjuvant. Freund's Complete Adjuvant was used for the
35 first injection and Freund's Incomplete Adjuvant was used for the second injection. The antiserum R102 reacted strongly with the BB region in ELISA while no reactivity

to the M3 peptide could be demonstrated. The antiserum R102 was therefore suitable for the detection of BB on the surface of staphylococci.

5 Immunoassay for the detection of peptides on the surface of *S. xylosus*

Cells harbouring the different constructs were grown at 37°C over night in broth supplemented with Chloramphenicol (20 mg/l). The cells were washed two times in PBS. 15-well multitest slides (Flow laboratories) were incubated with coating buffer (15 mM Na₂CO₃, 35 mM NaHCO₃, pH 9.6) in a humid chamber for 30 minutes at room temperature. The coating buffer was displaced by one drop of bacteria (10⁷ bact./ml) in PBS and the slides were incubated in a humid chamber for 30 minutes at room temperature.

15 Unbound bacteria were washed away with PBS and the monolayer of cells was fixed for a few seconds with 1% glutaraldehyde in PBS. Finally the slides were washed in distilled water and air dried before storage at -20°C. The rabbit antisera were diluted 1:1000 in PBS, one drop added to each well, and incubated in a humid chamber for 30 minutes at room temperature. After washing 4 times with PBS, the slides were incubated with biotinylated anti-rabbit IgG-molecules (15 µg/ml) (Vector, USA) for 30 minutes and washed once again in PBS before the addition

25 of avidine-conjugated fluorescein isothiocyanate (FITC)(50 µg/ml)(Vector, USA) for 30 minutes incubation. Finally, the slides were washed, ethidium bromide was added to visualize bacterial DNA, and examined under a UV-microscope.

30 Legend to figures

Fig. 1 A

A schematic drawing of the gene encoding staphylococcal protein A with its different regions. S is the signal sequence. E, D, A, B and C encode the highly homologous IgG-binding domains. X encodes the cell wall spanning region and M the membrane anchoring region.

35

Fig. 1 B

An illustration of processed protein A bound to the outer cell surface of staphylococci.

Fig. 2 A

5 The plasmids pSBBmp18XM and pSBBm3XM described in Example 1. Note that the BB-region in this case is the serum albumin binding region based on streptococcal protein G. Abbreviations: bla, β -lactamase encoding gene; cat, chloramphenicol acetyl transferase encoding gene; 10 OriE, origin of replication from E. coli; OriS, origin of replication from S. aureus.

Fig. 2 B

An illustration of the processed and secreted expression products, encoded from plasmids pSBBmp18XM and 15 pSBBM3XM, bound to the cell surface of staphylococci.

Fig. 3

Immunofluorescence of immobilized *S. xylosus* cells expressing BB on the cell surface. The reactivity is obtained with BB-specific antisera (R120). Note that the 20 internal part of the cells is enlightened by the ethidium bromide staining.

Fig. 4

Immunofluorescence of immobilized *S. xylosus* cells expressing BBM3 on the cell surface. The reactivity is obtained with M3-specific antisera (R102). Note that the 25 internal part of the cells is enlightened by the ethidium bromide staining.

Fig. 5

Immunofluorescence of immobilized *S. xylosus* cells 30 expressing BBM3 on the cell surface. No reactivity could be obtained using preimmune sera. Note that the internal part of the cells is enlightened by the ethidium bromide staining.

Fig. 6

Schematic representation of the gene encoding the scFv fragment of the mouse antilysozyme antibody D1.3. The annealing sites for the different oligonucleotides are indicated by the arrows.

Fig. 7

Schematic description of the pSBB-scFv-XM plasmid encoding the BB-scFv-XM fusion protein. Some relevant restriction enzyme recognition sites are shown. CAT: chloramphenicol acetyl transferase.

Fig. 8

Polaroid image of an ethidium bromide stained and UV [254 nm] exposed gel, containing the different DNA fragments of the pSBB-scFv-XM plasmid obtained after digestion with the indicated restriction enzymes. Panel A: Plasmid prepared from S. xylosus cells; panel B: plasmid prepared from E. coli cells. Marker DNA fragment sizes are indicated [left].

Fig. 9

Schematic representation of the expected orientation in the S. xylosus host cell wall of the BB-scFv-XM fusion protein encoded by the pSBB-scFv-XM plasmid.

Fig. 10

Schematic description of the pSBG3XM plasmid harbored by the S. xylosus cells used for the oral administration of the mice. S, signal peptide derived from staphylococcal protein A [SPA]; BB, serum albumin binding region derived from streptococcal protein G; G3, the three-copy RSV epitope; XM, the cell wall anchoring region from SPA; bla, beta-lactamase; OriE, origin of replication for E. coli; OriS, origin of replication for S. xylosus; cat, chloramphenicol acetyl transferase; Pspa, promoter from the spa operon.

Fig. 11

Bardiagram representation of the results from the ELISA assay for the detection of anti-BBG3 antibodies present in the blood of the immunized mice at different

time points after the first oral distribution.

EXAMPLE I

By NotI - NdeI digestion of the E. coli-staphylococci
5 shuttle vector pRIT16 (Abrahmsén et al., Nucl. Acids Res.
14, 7487-7500 (1986)), the gene for staphylococcal protein
A (SPA) was replaced for a NotI - NdeI gene fragment re-
stricted from plasmid pEZZ318T (Nygren et al., J. Molec.
Recogn. 1, 69-74 (1988)) encoding a synthetic divalent
10 IgG-binding domain, ZZ, preceded by the transcription,
translation and secretion signals of SPA. The resulting
plasmid pSZZmpl8T contained the origins of replication for
both E. coli and Staphylococcus aureus. A gene fragment
encoding the IgG-binding regions A, B and C plus the
15 cellwall spanning region X and membrane anchoring region M
(Fig. 1) of SPA, was restricted from plasmid pSpA8 (Uhlén
et al., J. Biol. chem. 259, 1695-1702 (1984)) using
HindIII and EcoRV, and inserted downstream of the mp18
multicloning site (Yanisch-Perron et al., Gene 33, 103-119
20 (1985)) in plasmid pSZZmpl8T, previously restricted with
the same enzymes. The resulting vector was denoted
pSZZmpl8ABCXM. This plasmid was digested with HindIII and
PstI thus deleting a gene fragment encoding regions A, B,
C and X and half of region M of SPA. The complete sequence
25 of region X and M could be restored applying a polymerase
chain reaction (PCR) strategy. A PCR amplification was
performed using STST34 as the upstream primer, STST33 as
the downstream primer and plasmid pSpA8 as DNA template.
The upstream primer generated a HindIII recognition site
30 by its non-annealing 5' sequence and the downstream primer
overlapped a native PstI recognition sequence in the M
region of SPA. The PCR amplified fragment could thus be
restricted with HindIII and PstI and subcloned to plasmid
pRIT28 (Hultman et al., Nucleos. and Nucleot. 7, 629-638
35 (1988)), previously restricted with the same enzymes,
yielding plasmid pRIT28XM. The nucleotide sequence of the
PCR subcloned fragment was verified by solid phase DNA

sequencing (Hultman et al., Nucl. Acids Res. 17, 4937-4946 (1989)). By HindIII-PstI restriction of pRIT28XM the gene fragment, encoding region X and half of region M of SPA, could be isolated and fused to the HindIII-PstI digested plasmid pSZZmpl18ABCXM (described above) resulting in plasmid pSZZmpl18XM, with complete and in frame regions X and M downstream of the mpl18 multicloning site. By NotI-EcoRI digestion of plasmid pSZZmpl18XM the ZZ encoding gene fragment could be replaced for a NotI-EcoRI fragment restricted from plasmid pB1B2mpl18 (Ståhl et al., J. Immunol. Meth. 124., 43-52 (1989)), encoding a serum albumin binding region of streptococcal protein G, denoted BB, preceded by the transcription, translation and secretion signals of SPA. The resulting vector pSBBmpl18XM (Fig. 2A) contained the origins of replication for both E. coli and Staphylococcus aureus. The mpl18 multicloning site in the general expression vector pSBBmpl18XM was removed by EcoRI-HindIII restriction. A gene fragment, encoding a highly repetitive peptide M3 (Ståhl et al., Gene 89, 187-193 (1990)), was cut out from plasmid pRIT28M3 (Ståhl et al., Gene 89, 187-193 (1990)) where the stop codon ending the M3 sequence first was removed by site directed solid phase in vitro mutagenesis (Hultman et al., Nucl. Acids Res. 18, 5107-5112 (1990)). The M3 encoding, EcoRI-HindIII restricted, gene fragment was ligated to the similarly digested pSBBmpl18XM, yielding plasmid pSBBM3XM (Fig. 2A). The M3 polypeptide is derived from the highly immunogenic C-terminal part of the malaria blood-stage antigen Pf155/RESA (Berzins et al., Proc. Natl. Acad. Sci. USA 83, 1065-1069 (1986)).

Plasmid pSBBmpl18XM encode a tripartite fusion protein, comprising the signal peptide from SPA, the serum binding BB part derived from streptococcal protein G and the cellwall binding XM regions from SPA. Upon secretion through the cell membrane, the signal peptide is cut off. Plasmid pSBBM3XM encode a tetrapartite fusion protein where the malarial antigenic peptide M3 is placed between

15

the BB and XM regions (Fig. 2B).

Plasmids pSBBmp18XM and pSBBM3XM are transformed to protoplasts prepared from Staphylococcal xylosus (see under "Starting materials" for details). As shown in Table 1, an immunoassay using polyclonal rabbit antisera specific for BB or M3, respectively, revealed that S. xylosus cells harbouring plasmid pSBBmp18XM expressed BB on the cell surface (Fig. 3) whereas pSBBM3XM containing cells expressed both BB and M3 on the cell surface (Fig. 4), indicating that both the secretion signals and the cell wall binding moiety, XM, are functional when expressing recombinant fusion proteins by this manner. S. xylosus cells without plasmid were negative for both BB and M3 specific antisera, respectively, and preimmune sera were negative in all cases (Fig. 5).

TABLE 1

S. xylosus cells harbouring	Rabbit antisera		
	Preimmune	BB-specific (R120)	M3-specific (R102)
pSBBmp18XM	-	+	-
pSBBM3XM	-	+	+
No plasmid	-	-	-

EXAMPLE II

By PCR amplification using the oligonucleotides primer pairs KS1/2 and KS3/4 respectively, on the plasmid templates pHERAT and pLERAT harbouring the variable domains of the heavy [pHERAT] and light [pLERAT] chains of the anti-lysozyme antibody D1.3 [McCafferty et al 1990, Nature 348, 552-554], the gene fragments encoding the two variable domains could be isolated. By the use of the primer-incorporated suitable restriction enzyme recogni-

tion sites Eco RI and Bam HI, the fragments were inserted into pRIT28, adapted for solid phase sequencing.

After confirmation of the correct sequences, the resulting plasmids pRIT28-VH and pRIT28-VL were separately
5 used as templates in a subsequent PCR amplification using oligonucleotide primer pairs KS6/2 [pRIT28-VH] and KS3/5 [pRIT28-VL], respectively. Approximately five [5] nanograms each of the resulting PCR products were subsequently mixed, heated to 85°C and thereafter let to cool to room
10 temperature. After addition of 0.5 units of Taq polymerase [Perkin Elmer corp.], PCR buffer, two standard cycles of PCR were run in order to obtain double stranded DNA. This procedure results in the linking of the two immunoglobulin encoding gene fragments due to the overlapping sequences
15 incorporated during the second PCR by the KS5 and KS6 oligonucleotides. The linking DNA sequence encodes a highly flexible, 15 amino acid residues bridging peptide between the two immunoglobulin domains. The resulting 730 basepair gene fragment thus encodes a single chain Fv
20 [scFv] fragment of the anti-lysozyme antibody D1.3 [Fig 6] as described by the schematic representation:



25 in order to obtain sufficient amounts for further cloning of the scFv encoding fragment, 20 additional PCR cycles were executed employing the outer primers KS3 and KS2. The resulting PCR product was restricted with restriction enzymes Eco RI and Bam HI and subsequently ligated into the
30 cloning vector pUC19. After confirmation of the sequence, a clone containing the correctly assembled scFv gene fragment was Eco RI and Bam HI restricted and the 730 basepair fragment was inserted into the Eco RI and Bam HI sites of the E. coli expression vector pRIT24 [Hammerberg et al
35 Proc. Natl. Acad. Sciences, USA, 86, 4367-4371]. The resulting construct pRIT24-scFv thus encodes the tripartite fusion ZZ-scFv-BB. E. coli cells transformed with the

17

pRIT24-scFv were grown over night at 30°C in Tryptic Soy Broth + Yeast Extract supplemented with ampicillin [100 mg/l].

In order to investigate the stability and biological activity of the recombinant ZZ-scFv-BB fusion protein, culture medium from the over night fermentation was passed through Human Serum Albumin [HSA] and Hen Egg-White Lysozyme [HEL] Sepharose columns respectively. Proteins eluted from the columns by 0.5 M HAC/NH₄Ac pH2.8 were lyophilized and analyzed by SDS-PAGE. The major band for both the HSA- and HEL-affinity purified material was found to be of full-length. The successful affinity purification of the ZZ-scFv-BB fusion protein using HEL suggests that the scFv immunoglobulin fragment is able to fold into a native, biologically active structure although flanked by the two affinity tails ZZ and BB.

Described in Example 1 is the construction of the shuttle vector pSBBmp18XM, able to replicate both in E. coli and Staphylococcus cells. In order to adapt this vector for the insertion of the scFv fragment, the mp18 linker was substituted with the shorter mp8 linker derived from M13mp8 [Messing et al, 1982, Gene 19, 269-276] to yield pSBBmp8XM. The scFv encoding gene fragment was released from the pUC19-scFv plasmid by Eco RI and Bam HI restriction and subsequently ligated into the pSBBmp8XM vector.

S. xylosus cells were transformed with the resulting pSBB-scFv-XM construct [Fig 7] and viable colonies were grown over night at 37°C in TSB supplemented with chloramphenicol [20 mg/l] for plasmid preparation. Restriction enzyme mapping of the pSBB-scFv-XM construct, prepared from the transformed staphylococci cells, was in agreement with the expected result [Fig 8]. This shows that the pSBB-scFv-XM construct is genetically stable within the Staphylococcus host.

This construct encodes the BB-scFv-XM fusion protein designed to be incorporated into the host cellwall [Fig 9].

EXAMPLE III

5 **Development of specific antibodies in mice after oral administration.**

A gene encoding a peptide, G3, containing three [3] copies of the Respiratory syncytial virus [RSV] glycoprotein G epitope [Trudel et al (1991), Virology 185: 749-10 757] C-terminal repeat sequences, VSICSNNPTCWAISKN, was constructed using the oligonucleotides: TH5:5'-ATGTATCTA TCTGCTCTAACAACCCGACTTGTGGGCTATCTCCAAAA-3' and TH6: 5'-ACATTTTTGGAGATAGCCCAACAAGTCGGGTTGTTAGAGCAGATAGAT-3' according to the polymerization concept described for the 15 construction of the M3 peptide described in Example I and inserted into pRIT28E yielding pRIT28EG3. The nucleotide sequence of the G3 encoding gene was verified by solid phase DNA sequencing [Hultman et al (1989) Nucl. Acids Res. 17: 4937-4946]. The G3 gene fragment was cut out from 20 pRIT28EG3 with EcoRI and HindIII and ligated to the similarly digested pBB2mpl8 vector [Stahl et al (1989), J. Imm. Meth. 124: 43-52]. The resulting vector, pBBG3 [5153 bp], encodes a fusion protein designated BBG3 [30.9 kDa], consisting of the serum albumin binding region 25 from streptococcal protein G [SPG] and the tripeptide repeat. *E. coli* cells harboring the pBBG3 plasmid were grown over night at 37°C in 500 ml tryptic soy broth [30 g/l] supplemented with ampicillin [100 mg/l]. The fusion proteins were purified from the medium and the periplasmic 30 space by affinity chromatography on HSA-Sepharose according to Nygren et al [J.Mol.Recognit. 1:69-74].

The G3 encoding gene fragment was recovered from pRIT28EG3 plasmid restricted with EcoRI and HindIII after the removal of the stop codon ending the G3 sequence by 35 solid phase site directed mutagenesis as described for the M3 gene in Example I. The restricted fragment was ligated to the similarly restricted pSBBmpl8XM, yielding plasmid

pSBBG3XM [Fig. 10]. Plasmid pSBBG3XM encodes a tetrapeptide fusion protein, comprising the signal peptide from SPA, the serum albumin binding BB region derived from SPG, the RSV antigenic peptide G3 and the cellwall binding XM regions from SPA.

Plasmids pSBBmpl8XM and pSBBG3XM were transformed to protoplasts prepared from Staphylococcus xylosus [for details, see "Starting materials"] and the cells grown over night. Four female mice OF1 [IFFA CREDO, France] six weeks of age at the beginning of the experiments, were each orally given 10^{10} S. xylosus bacteria [counted by microscope using an improved Neubauer counting chamber] from over night cultures harboring the pSBBG3XM plasmid each tuesday, wednesday, thursday and friday during a three week period followed by a second period of three weeks after day 43. Blood was collected individually at days 21, 28, 35 and 63 and tested for the presence of anti-BBG3 antibodies using purified BBG3 protein as coating antigen in an ELISA assay: microtiter plates were coated over night with a 1.25 µg/ml solution of BBG3, followed by a two hours saturation with 1% skimmed milk in PBS. The blood samples from the immunized mice were subsequently loaded and after incubation and subsequent extensive rinse, the bound antibodies were detected using anti-mouse IgG-alkaline phosphatase conjugate [Sigma Inc. reagent No. A1902] together with chromogenic alkaline phosphatase substrate allowing monitoring at 405 nm. Tests were done in triplicates with serum taken at day zero to be used as negative control and a rabbit anti-BBG3 polyclonal sera was used as positive control. The results shown in Fig. 11 show the development of BBG3-specific immune responses in all four animals during the 63 days of treatment.

CLAIMS

1. Recombinant DNA sequence comprising a first DNA fragment coding for a first amino acid sequence operating as a signal peptide operable in a Gram positive host, operatively linked to a second DNA fragment coding for a second amino acid sequence not naturally found on the surface of Gram positive bacteria and capable of selective interaction, said second DNA fragment being operatively linked to a third DNA fragment coding for a third amino acid sequence operable in a Gram positive host as a cell wall spanning and membrane anchoring sequence.

2. Recombinant DNA sequence according to claim 1, wherein said second amino acid sequence is capable of antigenic action.

3. Recombinant DNA sequence according to claim 1, wherein said second amino acid sequence is an antibody (immunoglobulin) or active fragment thereof.

4. Recombinant DNA sequence according to any of claims 1 to 3, wherein said third DNA fragment codes for the cell wall spanning and membrane anchoring region of staphylococcal protein A or streptococcal protein G.

5. Recombinant DNA sequence according to any of claims 1 to 4, wherein said first DNA fragment originates from a Gram positive bacterial cell.

6. Recombinant DNA sequence according to claim 4 or 5, wherein said third DNA fragment codes for the cell wall spanning and membrane anchoring region of staphylococcal protein A.

7. Recombinant DNA sequence according to claim 6, wherein said first DNA fragment codes for the signal peptide of staphylococcal protein A.

8. Recombinant DNA sequence according to any preceding claim, wherein said second DNA fragment codes for an amino acid sequence capable of eliciting an immunogenic response useful for vaccination purposes or for the production of antibodies.

9. An expression vector or plasmid containing a recombinant DNA sequence according to any preceding claim and capable of replicating in a Gram positive bacterial host.

5 10. A Gram positive bacterial cell harbouring a recombinant DNA sequence according to any of claims 1 to 8 or transformed by a vector or plasmid according to claim 9.

10 11. A process for selective isolation or identification of Gram positive bacterial cells according to claim 10 from a heterologous population of such cells carrying different recombinant surface receptor structures, comprising the step of allowing said heterologous population of cells to interact with a specific interacting partner
15 enabling identification and/or isolation of cells carrying one specific recombinant surface receptor structure.

12. A process according to claim 11, wherein said receptor structures are constituted by antibodies or active fragments thereof.

20 13. A process according to claim 11 or 12, wherein said interacting partner in an immobilized form is used for isolation of cells carrying said specific structure.

14. A process according to claim 13, wherein said interacting partner is immobilized on a solid support.

25

30

35

FIG. 1A



FIG. 1B

Cell wall Cell membrane





FIG. 7






FIG. 2A






FIG. 2B



3/6




FIG.3




FIG.4

4/6




FIG. 5

5/6

FIG. 6




FIG. 8





FIG. 9



6/6






FIG. 11

DEVELOPMENT of BBS ANTIBODY after ORAL ADMINISTRATION of SXYLOSUS harboring the plasmid pSBBG3XM



INTERNATIONAL SEARCH REPORT

International Application No **PCT/SE 92/00304**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC5: C 12 N 15/62, A 61 K 39/00, C 12 N 5/00		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC5	C 12 N; A 61 K; C 07 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched ⁸		
SE,DK,FI,NO classes as above		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP, A1, 0244221 (GENENTECH, INC.) 4 November 1987, see page 13, lines 7-17; page 8, lines 25-32; claims 1,2,7,14,20,22	1-2,5,9,10
Y	--	1-10
A	Science, Vol. 240, 1988 Brian K. Kobilka et al.: "Chimeric alfa2-,beta2-Adrenergic Receptors: Delineation of Domains Involved in Effector Coupling and Ligand Binding Specificity", see page 1310 - page 1316	1-10
Y	EP, A1, 0324162 (PLUCKTHUN ANDREAS ET AL) 19 July 1989, see the whole document	1-10
	--	
<p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
14th August 1992		1992 -08- 19
International Searching Authority		Signature of Authorized Officer
SWEDISH PATENT OFFICE		 Mikael G:son Bergstrand

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Gene, Vol. 89, 1990 Stefan Ståhl et al.: "A general strategy for polymerization, assembly and expression of epitope-carrying peptides applied to the Plasmodium falciparum antigen Pf155/RESA", see page 187 - page 193 see especially page 188, col. 1, lines 48-52; sid 190, col. 2, lines 14-17 ---	7,8
Y	WO, A1, 8907140 (COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION) 10 August 1989, see the whole document ---	1-10
Y	Chemical Abstracts, volume 115, no. 17, 27 October 1986, (Columbus, Ohio, US), C J Langford et al: "Anchoring a secreted Plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity ", see, abstract 147518v, & Mol. Cell. Biol. 1986, 6(9), 3191-3199 ---	1-10
Y	EP, A2, 0109861 (BIO-RESPONSE INC.) 30 May 1984, see the whole document ----- ---	11-14

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/SE 92/00304**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 01/07/92. The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0244221	87-11-04	JP-A- 62272990	87-11-27
		US-A- 4859609	89-08-22
		US-A- 5030576	91-07-09
EP-A1- 0324162	89-07-19	AU-D- 2761788	89-07-06
		DE-A- 3744595	89-07-13
		JP-A- 2000799	90-01-05
WO-A1- 8907140	89-08-10	AU-D- 3045389	89-08-25
		EP-A- 0398944	90-11-28
EP-A2- 0109861	84-05-30	AU-B- 573193	88-06-02
		AU-D- 2158783	84-05-31
		CA-A- 1198694	85-12-31
		JP-A- 59151886	84-08-30
		US-A- 4659655	87-04-21